CORRESP Filing
Immix Biopharma, Inc.
Date: Jan. 16, 2026 · CIK: 0001873835 · Accession: 0001493152-26-002680
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292665
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Mr. Tyler Howes Immix Biopharma, Inc. Registration Statement on Form S-3 Filed January 9, 2026 File No: 333-292665
Dear Mr. Howes,
Immix Biopharma, Inc. (the " Registrant ") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-292665), be accelerated by the U.S. Securities and Exchange Commission (the " Commission ") to become effective on Tuesday, January 20, 2026 , at 5:00 p.m ., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow, Esq. and Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (212) 885-5358 or Ms. Murawsky at (215) 569-5732 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very
truly yours,
IMMIX
BIOPHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm January 16, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Tyler Howes Re: Immix Biopharma, Inc. Registration Statement on Form S-3 Filed January 9, 2026 File No: 333-292665 Dear Mr. Howes, Immix Biopharma, Inc. (the " Registrant ") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-292665), be accelerated by the U.S. Securities and Exchange Commission (the " Commission ") to become effective on Tuesday, January 20, 2026 , at 5:00 p.m ., Eastern Time, or as soon as reasonably practicable thereafter. The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. The Registrant hereby authorizes Leslie Marlow, Esq. and Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (212) 885-5358 or Ms. Murawsky at (215) 569-5732 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted. Very truly yours, IMMIX BIOPHARMA, INC. By: /s/ Gabriel Morris Name: Gabriel Morris Title: Chief Financial Officer cc: Leslie Marlow, Esq., Blank Rome LLP Melissa Murawsky, Esq., Blank Rome LLP